| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 8.793 | 10.713 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - |
| Total Income - EUR | 8.793 | 10.713 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - |
| Total Expenses - EUR | 4.119 | 1.802 | 82 | 0 | 0 | 0 | 0 | 0 | 0 | - |
| Gross Profit/Loss - EUR | 4.674 | 8.911 | -82 | 0 | 0 | 0 | 0 | 0 | 0 | - |
| Net Profit/Loss - EUR | 4.411 | 8.590 | -82 | 0 | 0 | 0 | 0 | 0 | 0 | - |
| Employees | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - |
Check the financial reports for the company - Olvidan Med Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - |
| Current Assets | 12.766 | 21.438 | 21.076 | 20.447 | 20.051 | 19.671 | 19.235 | 19.295 | 19.236 | - |
| Inventories | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - |
| Receivables | 10.017 | 17.720 | 17.420 | 17.100 | 16.769 | 16.451 | 16.086 | 16.136 | 16.087 | - |
| Cash | 2.748 | 3.719 | 3.656 | 3.347 | 3.282 | 3.220 | 3.149 | 3.158 | 3.149 | - |
| Shareholders Funds | 10.180 | 18.666 | 18.268 | 17.933 | 17.586 | 17.252 | 16.870 | 16.922 | 16.871 | - |
| Social Capital | 45 | 45 | 44 | 43 | 42 | 41 | 40 | 41 | 40 | - |
| Debts | 2.586 | 2.772 | 2.808 | 2.514 | 2.466 | 2.419 | 2.365 | 2.373 | 2.365 | - |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "4618 - 4618" | |||||||||
| CAEN Financial Year |
4618
|
|||||||||
Comments - Olvidan Med Srl